The largest database of trusted experimental protocols
> Disorders > Congenital Abnormality > Foramen Ovale, Patent

Foramen Ovale, Patent

Foramen Ovale, Patent: A condition where the foramen ovale, a normal fetal opening between the right and left atria of the heart, fails to close after birth.
This can lead to right-to-left shunting of blood and various health complications.
The condition is often asymptomatic but may be detected incidentally or during evaluation for other cardiac issues.
Proper diagnosis and management are important to prevent potential complications.
This MeSH term provides a concise overview of the condition for researchers studying patentd related to the foramen ovale and its management.

Most cited protocols related to «Foramen Ovale, Patent»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Aneurysm Aortic Valve Insufficiency Ascending Aorta Atrial Septal Defects Atrium, Left Echocardiography, Contrast Foramen Ovale, Patent Heart Valves Heart Ventricle Mitral Valve Patients Radionuclide Imaging Saline Solution Senile Plaques Septum, Atrial Thoracic Aorta Thrombus Tunica Intima Valves, Aortic
Studies have shown that ICD-9-CM codes for CHDs lack specificity and have poor diagnostic accuracy. (Cronk et al., 2003 (link); Frohnert et al., 2005 (link); Strickland et al., 2008 (link); Rodriguez et al., 2018 (link)) For example, 745.5 codes for both atrial septal defect (ASD), a true CHD, and patent foramen ovale (PFO), a normal newborn condition. The PFO, which may persist in 25% of adults, is usually clinically insignificant and asymptomatic, but potentially associated with strokes. The 745.4 codes for ventricular septal defect, a common congenital condition which may also be acquired in adults after a myocardial infarction. To investigate the validity of specific codes for identifying a true CHD, clinicians at participating sites reviewed medical records from a random sample of cases. Each site had different sample size and code selection (Table 2) based on number of cases with codes of interest, availability of medical records, and clinical review resources. Cases sampled had the following isolated codes potentially used for non-CHD conditions: 745.5, 745.4 in persons >40 years old, 746.85 (coronary artery anomaly), and 746.89/746.9 (other specified/unspecified heart anomaly).
Publication 2018
Adult Artery, Coronary Atrial Septal Defect 5 Cerebrovascular Accident Congenital Disorders Congenital Heart Defects Diagnosis Foramen Ovale, Patent Infant, Newborn Myocardial Infarction Ventricular Septal Defects
We used data from the Stanford Translational Research Integrated Database Environment (STRIDE) which contains clinical information of over 2 million pediatric and adult patients cared for at Stanford Health Care and Stanford Children’s Health from 1995 to 2015, including 20 million patient encounters with transcriptions of all inpatient and outpatient clinical notes, pathology and radiology reports, medication lists, lab results, and vitals data. This data source was accessed under approved Institutional Review Board protocols.
Through a previously validated and implemented text-processing pipeline to analyze clinical data [8 (link)–10 (link)], we used Unitex [11 ] as an annotator and over 10 clinical ontologies to extract positive present mentions of disease concepts from all clinical notes. We excluded uninformative phrases based on the term frequency analysis [12 (link)] and kept only terms with more than 4 characters to avoid ambiguity. We also flagged negative mentions (e.g. “ruled out stroke”) and determined if a term was from patients’ history or family history sections of a note [13 (link)]. The product of this pipeline is a list of present, positive mentions of biomedical concepts in each patient note.
We identified all patients who had their first ICD-9 documentation of CS/TIA at age 40 or older in either inpatient and outpatient encounters. The inclusion criteria using ICD-9 diagnosis codes are stroke (434 and 436) and TIA (435.9). These ICD-9 codes were selected because have been previously shown to have high specificity and sensitivity for ischemic stroke when confirmed with chart review[14 ].
From the CS/TIA patients identified using these codes, some were removed from the cohort based on both ICD-9 and clinical text evidence that meets specific exclusion criteria to increase specificity for patients without these conditions. Patients who had ICD-9 diagnosis of carotid artery occlusion or stenosis (433.1), intracranial hemorrhage (431), and atrial septal defects (745.5) were excluded as these are identifiable etiologies of stroke. Patients with rheumatic heart disease (433.1) or prosthetic valve(s) (V43.3) were excluded as AF in these contexts belong to a separate entity, valvular AF, separate from AF of the general population. Those with hyperthyroid disease (242.9) were also excluded as this is a known reversible cause of AF. Patients who had clinical text evidence of rheumatic heart disease, prosthetic valve(s), and/or patent foramen ovale were also excluded.
The outcome of interest in this study is diagnosis of AF after CS/TIA. All patients who had history of AF were identified by ICD-9 code (427.31 and 427.32). Those positive for AF were defined as patients over 40 years old with CS/TIA whose first ICD-9 documentation of AF was at least 30 days after first episode of CS/TIA. We used a 30-day cutoff to exclude patients who may have had delayed documentation of AF related to their hospitalization for initial stroke. Those negative for AF were defined as patients with CS/TIA with no ICD-9 documentation of AF during the extent of their follow-up as documented in their records.
Basic demographic information such as age at time of CS/TIA and sex were obtained from the structured fields of their records. Risk factors were extracted based on ICD-9 documentation at any time point of patients’ records to enable us to better capture those patients’ chronic conditions. Risk factors assessed were hypertension (HTN), diabetes (DM), obesity defined by BMI>30, systolic and/or diastolic heart failure (CHF), coronary artery disease (CAD), peripheral vascular disease (PVD), chronic kidney disease (CKD) stage III, IV, V, aortic valve disease, mitral valve disease, tricuspid valve disease, and pulmonary valve disease. Such clinical factors are well known to be risk factors for AF [15 (link),16 (link)]. A comprehensive list of conditions covered by each respective ICD-9 used is detailed in the supplemental table.
We randomly split the total cohort into 2 groups: the first for model derivation (80%) and the second for model validation (20%). Candidate predictor variables include age, sex and all the risk factors described above. Univariable logistic regression was first applied to identify the association between each of the predictor variables and diagnosis of AF in the derivation cohort. A multivariable logistic regression model with stepwise variable selection was then trained on the derivation cohort to identify predictors of AF and to estimate their relative predictive power. A simplified risk stratification system was developed based on the beta coefficients of the multivariable logistic regression model as validated by previously published methods [17 (link)]. Points assigned to each significant risk factor were obtained by dividing each by the lowest coefficient and rounding to the nearest integer [18 (link)]. We then calculated a patient’s risk score by summing up all points that correspond to the risk factors present in the given patient’s record.
We assessed model discrimination by using the c-statistic, or area under the curve (AUC) of the Receiver Operating Characteristic (ROC) Curve, which defines how well a model or prediction rule can discriminate between patients who are and are not positive for an event. We then used the Cochran-Armitage trending statistic to assess the ability of the risk score system to differentiate low-risk from high-risk patients. The scoring system was applied to and evaluated in the derivation cohort to assess its applicability. The performance of HAVOC and CHA2DS2-Vasc was compared at a score of 4, which was the cutoff value between the low and medium risk strata for both scoring systems. McNemar’s Chi- squared tests were used to compare the sensitivity, specificity, and accuracy. Positive predictive values (PPV) and negative predictive values (NPV) were compared using a test score developed by Leisenring et al. [19 (link)] All analyses were performed using open source statistical program R Version 3.2.2 [20 ].
Publication 2017
Adult Arterial Occlusion Atrial Septal Defects Carotid Arteries Cerebrovascular Accident Character Children's Health Chronic Condition Chronic Kidney Diseases Conditioning, Psychology Coronary Artery Disease Dental Occlusion Diabetes Mellitus Diagnosis Discrimination, Psychology Ethics Committees, Research Foramen Ovale, Patent Heart Failure, Diastolic High Blood Pressures Hospitalization Hypersensitivity Hyperthyroidism Inpatient Intracranial Hemorrhage Lung Diseases Mitral Valve Obesity Outpatients Patients Peripheral Vascular Diseases Pharmaceutical Preparations Rheumatic Heart Disease Stenosis Stroke, Ischemic Systole Transcription, Genetic Valve Disorder, Aortic Valves, Tricuspid X-Rays, Diagnostic
The CHD families analysed in this study were recruited from multiple pediatric cardiology and clinical genetics centres from the UK, USA, Canada, Germany, Belgium and Saudi Arabia, and includes families of both European and non-European ancestry (Supplementary Table 1). In addition to single center recruitment, four multi-center cohorts were included: DDD study, UK10K project, Competence Network for Congenital Heart Defects (Germany) and published data7 (link) from the Pediatric Cardiac Genetics Consortium (PCGC). The breakdown by centre/study is shown in Supplementary Table 2, and by phenotype in Supplementary Table 3. Our study focused on severely affected NS-CHD cases needing surgical intervention and S-CHD cases with clinically relevant structural heart defects. Patients were assigned to the S-CHD cohort if they showed a distinct facial gestalt or had at least one reported extra-cardiac malformation. Local Institutional review boards have approved all studies with written consent for patients or parents depending on the local requirements. Within the participating institution, the phenotype status in cases was evaluated by clinical examination, two-dimensional echocardiography, magnetic resonance imaging and cardiac catheterization, surgical or physician reports and sample description provided by deposited study files. We excluded mild cardiovascular lesions, such as an existing preterm patent ductus arteriosus and patent foramen ovale, as well as isolated extra-cardiac cardiovascular lesions, such as arterial tortuosity from the analysis. Cardiac and extra-cardiac phenotypes were translated to the current EPCC coding version (April 2015)27 (link) and HPO terminology28 (link) (Supplementary Table 3). In total 1,365 trios, 68 probands from 32 multi-sibling families and 458 singleton probands were sequenced and analysed.
We also assembled a collection of 12,031 control exomes of European ancestry comprised of two datasets using similar exome capturing platforms and applying an identical processing pipeline to that used for the CHD cohorts. The first dataset incorporates 7,301 exomes (3,654 females, 3,647 males) of unaffected parents from probands not suffering from CHD in the Deciphering Developmental Disorders cohort6 (link). The second control dataset consisted of 4,730 exomes (2,464 females, 2,266 males) of seemingly healthy blood donors as part of the INTERVAL study29 (link).
Publication 2016
2D Echocardiography Arterial Tortuosity Syndrome Cardiovascular System Catabolism Catheterizations, Cardiac Congenital Heart Defects Developmental Disabilities Donor, Blood Ethics Committees, Research Europeans Exome Face Females Foramen Ovale, Patent Heart Males Operative Surgical Procedures Parent Patent Ductus Arteriosus Patients Phenotype Physical Examination Physicians TRIO protein, human
After the procedure, mothers were hospitalized overnight. The fetus was assessed by ultrasound later in the same day and the following day before planned maternal discharge. Patients received follow-up at either our center or the referring institution. Echocardiography was performed at intervals determined by the primary fetal cardiologist. Anatomic and Doppler variables from the most recent prenatal study were used for analysis. A single echocardiographer independently confirmed all measurements from the primary images. Z scores were calculated relative to estimated gestational age on the basis of unpublished fetal norms that were derived from data collected at Children’s Hospital Boston between 2005 and 2007 on 232 normal fetuses (see the online-only Data Supplement for Z-score equations). Because all of the relevant left heart structures are normally related to gestational age in a linear fashion, growth rates may be estimated as the change in dimension per unit of time (e.g., millimeters per week). “High” LV pressure was defined as a maximum instantaneous MR jet predicting a gradient of ≥20 mm Hg or, if there was no MR, as a maximum instantaneous AS gradient ≥16 mm Hg (in most patients with an MR jet predicting a 20 to 25 mm Hg gradient, the AS gradient was within 4 to 8 mm Hg).
Postnatal management varied with the anatomy at birth and the institution providing care. We characterized outcome among surviving patients as biventricular circulation from birth (no univentricular staging procedures), biventricular circulation after initial univentricular palliation (i.e., neonatal stage 1 procedure, with or without subsequent palliative procedures, later taken down to biventricular circulation), or single-ventricle circulation (ie, a definitive or intermediate univentricular circulation at the time of cross-sectional follow-up). A biventricular circulation was defined as one in which the LV was the sole source of systemic output, with no intracardiac or great arterial shunts except possibly a patent foramen ovale or atrial septal defect.
Publication 2009
Arteries Atrial Septal Defects Birth Blood Circulation Time Cardiologists Care, Prenatal Dietary Supplements Echocardiography Echocardiography, Doppler Fetus Foramen Ovale, Patent Gestational Age Heart Infant, Newborn Patients Pressure Ultrasonography Univentricular Heart

Most recents protocols related to «Foramen Ovale, Patent»

For this prospective, single-center study, patients were recruited between June 1st, 2020 and July 1st, 2020. Data were obtained from medical records of adult patients (18 years of age or older) with laboratory-confirmed COVID-19 hospitalized in the intensive care unit (ICU) of a high complexity hospital from Buenos Aires, Argentina. Data registration included demographic, clinical and laboratory information, severity scores, the radiographic assessment of lung edema (RALE) score,8 (link) and mechanical ventilation measurements. The number of patients who died or been discharged, and those that stayed in ICU until August 31st, 2020 was recorded. Additionally, ICU length of stay was determined.
TTE was performed within the three days after ICU admission. Non-inclusion criteria were therapeutic effort adaptation, extracorporeal circulation membrane or inhaled nitric oxide requirement, obesity (body mass index > 30 kg/m2), history of chronic lung disease defined by spirometry as forced expiratory volume in the first second/forced vital capacity <0.75 or pulmonary hypertension defined as pulmonary systolic blood pressure >35 mmHg by any method of assessment, patent foramen ovale (PFO) or any defect in the cardiac interatrial or interventricular septum, history of Rendu Osler Weber Syndrome, and hepatic cirrhosis. Due to the fact that we routinely use TTE to assess the circulatory status of mechanically ventilated patients with COVID-19 in our ICU, TTE was considered a component of standard care. Nevertheless, contrast TTE is not routinely performed, therefore written patient's consent was solicited. Also written and oral information about the study was given to the families. The study was approved by the institutional ethics committee of our hospital under protocol number 5657. Our manuscript complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines for observational cohort studies9 (link) (Table E1 of Supplementary material).
Publication 2023
Acclimatization Adult Cardiovascular System COVID 19 Extracorporeal Circulation Foramen Ovale, Patent Heart Hereditary Hemorrhagic Telangiectasia Index, Body Mass Institutional Ethics Committees Liver Cirrhosis Lung Lung Diseases Mechanical Ventilation Obesity Oxide, Nitric Patients Pulmonary Edema Pulmonary Hypertension Radiography Spirometry Systolic Pressure Therapeutics Tissue, Membrane Ventricular Septum Vital Capacity Volumes, Forced Expiratory
This was an observational study conducted at the BC Women’s and Children’s Health Centre, a quaternary referral NICU, between January 2013 and December 2014 (retrospective) and from January 2015 to June 2016 (prospective). Population-based data of the total number of very low birth weight (VLBW) infants born at <34 weeks of gestation, including inborn and outborn, were obtained from the local neonatal database. All VLBW infants without any major congenital malformations or cardiac anomalies, except for PDA or patent foramen ovale, who were admitted to our NICU were enrolled in the study (Figure 1). A retrospective chart review was performed for all infants who underwent PDA ligation during Epoch I (January 2013 to December 2014), whereas prospective data were collected during Epoch II (January 2015 to June 2016). A dedicated comprehensive TNE program was introduced to preoperatively assess the PDA’s hemodynamic significance and to triage patients for ligation starting in January 2015. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the University of British Columbia Children and Women’s Research Ethics Board (No. H15-01343) and individual consent for this study was waived as data were already being collected for standard clinical care purposes (secondary use of data).
Publication 2023
Child Childbirth Congenital Abnormality Congenital Heart Defects EPOCH protocol Foramen Ovale, Patent Hemodynamics Infant Infant, Newborn Infant, Very Low Birth Weight Ligation Patients Pregnancy Woman
This is a retrospective study including pregnant women who were referred for fetal echocardiography to the Department of Fetal Diagnosis and Therapy at the University Hospital Giessen and Marburg from August 2012 to March 2018. Institutional review board approval was given (Protocol No. 209/11). Inclusion and exclusion criteria for healthy control fetuses were as previously described [9 (link)]. Inclusion criteria for the HLH group were the following:

Fetuses with severe MS or MA and/or severe AS or AA

Fetuses with borderline left ventricle (BLV) defined as a small—diminutive left ventricle (confirmed by the measurement of fetal LV z-scores [26 ]) with intrinsically open valves (MS and/or AS) [9 (link)].

In contrast to our previous work, we also included cases with restrictive foramen ovale (FO). The evidence of atrial restriction or premature closure of FO was diagnosed by dilated pulmonary veins or pulsatile flow in the pulmonary veins by spectral Doppler [14 (link), 20 (link)]. We decided to investigate cases with restrictive FO both in the overall HLH collective and in a generated subgroup analysis (with and without restrictive FO). Due to the assumed functional impairment of the RV in the case of restrictive FO, we suspected this condition to influence the myocardial deformation properties of RV significantly. Fetuses with further intracardiac abnormalities as well as structural or chromosomal anomalies were excluded. Furthermore, maternal conditions with possible hemodynamical effects, such as diabetes or preeclampsia acted as exclusion criteria as previously described [9 (link)].
According to the mentioned criteria above, two main groups were formed: the control group and the HLH group. For subgroup analysis HLH study population was first divided into cases with, and without LV-EFE. Second, HLH cases were divided in those with patent FO and those with restrictive FO. To support our hypothesis more convincingly we also analyzed our data without BLV diagnosis.
Full text: Click here
Publication 2023
Care, Prenatal Chromosome Aberrations Congenital Abnormality Diabetes Mellitus Diagnosis Echocardiography Ethics Committees, Research Fetal Diagnosis Fetus Foramen Ovale Foramen Ovale, Patent Heart Atrium Left Ventricles Maternal Inheritance Myocardium Pre-Eclampsia Pregnant Women Premature Birth Pulsatile Flow Therapeutics Training Programs Veins, Pulmonary
Transthoracic Echocardiography (model Vivid TM T9 manufactured by GE Healthcare, USA 2018) are recommended only in selected patients with ischemic stroke and additional characteristics like evidence of cardiac disease on history, examination, or electrocardiogram (ECG), suspected cardiac source of embolism (example infarctions in multiple cerebral or systemic arterial territories), suspected aortic disease or paradoxical embolism and for patients with no other identifiable causes of stroke [51 (link)]
Transthoracic Echocardiograms are read by cardiologists who are unaware of the patients’ neurologic condition or stroke subtype. Findings thought to be of potential diagnostic importance are extracted from the report view. Left atrial enlargement, patent foramen ovale (PFO)/atrial septal defect (ASD), low ejection fraction (EF35%), intracardiac thrombus, and valve vegetation or other valvular abnormalities being among them [52 (link)]
Full text: Click here
Publication 2023
Aortic Diseases Arteries Atrial Septal Defects Atrium, Left Cardiologists Cerebral Infarction Cerebrovascular Accident Congenital Abnormality Diagnosis Echocardiography Electrocardiography Embolism Embolism, Paradoxical Foramen Ovale, Patent Heart Heart Diseases Hypertrophy Nervous System Disorder Patients Stroke, Ischemic Thrombus
This retrospective study enrolled preterm infants who were born at < 32 weeks' gestation at our institution, between January 2014 and December 2018. Infants with congenital anomalies or congenital infections and infants who died before being discharged were excluded from the study population. Those who were lost to follow-up at a CA of 18–24 months were also excluded. Data on perinatal characteristics, clinical courses, PHN, and mode of respiratory support at a PMA of 36 weeks were collected. PHN was diagnosed at a PMA of 36 weeks using echocardiography based on the following findings: right-to-left or bidirectional shunt via patent ductus arteriosus or patent foramen ovale, velocity of tricuspid regurgitation ≥ 3 m/s, and left-deviated or flat configuration of the interventricular septum. Re-hospitalization due to a respiratory illness until a CA of 24 months and neurodevelopmental outcomes at a CA of 18–24 months were evaluated. Follow-up results were collected from the data achieved during regular outpatient follow-up schedule until 48 months of age, according to the institution's protocol. Hwang JK and Shin SH collected and reviewed the data from the electric medical records, and retrospectively categorized severity of BPD based on the three criteria. This study was approved by the Institutional Review Board of our institution (2109-008-1250). Obtaining informed consent was waived by the Institutional Review Board, and all methods were performed in accordance with the guidelines of the Human Research Protection Program.
Full text: Click here
Publication 2023
Childbirth Congenital Abnormality Echocardiography Electricity Ethics Committees, Research Foramen Ovale, Patent Homo sapiens Hospitalization Infant Infection Outpatients Patent Ductus Arteriosus Pregnancy Preterm Infant Respiratory Rate Tricuspid Valve Insufficiency Ventricular Septum

Top products related to «Foramen Ovale, Patent»

Vivid 7 and E9 are ultrasound imaging systems developed by GE Healthcare. The Vivid 7 is a high-performance cardiac and vascular ultrasound system, while the Vivid E9 is a premium cardiovascular ultrasound system. Both systems provide advanced imaging capabilities for diagnostic and clinical applications. The core function of these systems is to capture and display high-quality ultrasound images of the heart, blood vessels, and other anatomical structures.
Sourced in Israel
The Fortus 450MC is an additive manufacturing system designed for producing high-performance functional prototypes and production parts. It utilizes fused deposition modeling (FDM) technology to create 3D objects from a wide range of thermoplastic materials. The Fortus 450MC offers a build size of 16 x 14 x 16 inches and is capable of producing parts with intricate geometries and fine features.
Sourced in United States
The AcuNav is a medical device designed for intravascular ultrasound imaging. It provides real-time, high-resolution images of cardiovascular structures to assist healthcare professionals in diagnostic and treatment procedures.
Sourced in Belgium, Sweden
The Mimics Innovation Suite is a software platform that enables users to create, visualize, and analyze 3D models from medical imaging data. It provides tools for segmentation, surface rendering, and measurement analysis of anatomical structures.
Sourced in France
Plasmion is a laboratory equipment used for the separation and purification of plasma components. It utilizes advanced technology to efficiently extract and concentrate specific proteins, enzymes, or other biomolecules from plasma samples.
Sourced in United States, Germany
The Puregene DNA purification kit is a laboratory product designed for the extraction and purification of DNA from a variety of sample types. The kit utilizes a simple and efficient protocol to isolate high-quality genomic DNA that can be used in downstream applications such as PCR, sequencing, and genotyping.
Sourced in China
The TIANamp Blood DNA Kit is a nucleic acid extraction kit designed to efficiently isolate high-quality genomic DNA from whole blood samples. The kit utilizes a silica-based membrane technology to capture and purify DNA, providing a reliable and straightforward method for DNA extraction.
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.
Sourced in Germany, United States, Japan
The SOMATOM Force is a high-performance computed tomography (CT) system developed by Siemens. It is designed to deliver fast, precise, and efficient imaging capabilities for a wide range of clinical applications. The SOMATOM Force features advanced technologies that enable high-quality imaging while minimizing radiation exposure.
Sourced in United States
The LOGIQ S6 is a compact and portable ultrasound system designed for general imaging applications. It features a high-resolution display and offers real-time imaging capabilities.

More about "Foramen Ovale, Patent"

The foramen ovale is a natural opening in the heart that allows blood to bypass the lungs during fetal development.
After birth, this opening typically closes, but in some cases, it can remain patent (open).
Patent foramen ovale (PFO) is a relatively common condition, affecting up to 25% of the population.
While often asymptomatic, PFO can lead to serious health complications like strokes, migraines, and decompression sickness in divers.
Researchers studying PFO may utilize advanced imaging technologies like the Acunavr ultrasound system, the Somatom Force CT scanner, or the Logiq S6 ultrasound machine to diagnose and monitor the condition.
Genetic testing kits like the Puregene DNA purification kit or the TIANamp Blood DNA Kit can also help identify underlying genetic factors.
For researchers looking to optimize their PFO-related studies, tools like PubCompare.ai can be invaluable.
This AI-powered platform allows users to compare the latest literature, preprints, and patent data, helping to refine research protocols and enhance reproducibility.
By leveraging the insights gained from these resources, scientists can elevate their PFO research and uncover the best products and protocols for their work.
Whether you're investigating the causes, diagnosis, or management of patent foramen ovale, staying up-to-date with the latest advancements in the field is crucial.
By incorporating the right tools and technologies into your research, you can drive forward our understanding of this important cardiac condition and improve patient outcomes.